Litigation Details for Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Docket		Date Filed	2015-06-26
Court	District Court, N.D. West Virginia	Date Terminated	2017-09-12
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	6,551,620; 8,337,886; 8,496,965; 8,865,688
Link to Docket	External link to docket

Details for Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-26				External link to document
2015-06-26	117		These include: Patent No. 6,551,620 (“the ‘620 Patent”); Patent No. 8,337,886 (“…the ‘886 Patent”); Patent No. 8,496,965 (“the ‘965 Patent”); and 8,865,688 (“the ‘688 Patent”). The …CONSTRUING PATENT CLAIMS This patent infringement case involves four United States patents issued …‘620, ‘886, and ‘965 Patents, collectively referred to as the Otterbeck patents,1 contain two disputed…dispute one claim term in the ‘688 Patent. The Otterbeck patents cover a controlled	External link to document
2015-06-26	208		Regarding Infringement of United States Patent Number 8,865,688 by Dr. Falk Pharma GmbH, Salix Pharmaceuticals… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	226		Regarding Infringement of United States Patent Number 8,865,688 filed by Dr. Falk Pharma GmbH, Salix Pharmaceuticals… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	230		Post-Trial Brief Regarding Infringement of U.S. Patent No. 8,865,688 Other Document filed by Dr. Falk Pharma … 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	249		infringement and invalidity of U.S. Patent No. 8,865,688 (“the ‘688 patent”) (Dkt. No. 238). Significantly…Plaintiffs alleging infringement of claim 2 of the 688 patent are DISMISSED WITH PREJUDICE; Except for the limited…respecting the invalidity of claim 1 of the 688 patent, and consistent with the provisions of paragraph…counterclaims of invalidity with respect to the688 patent are DISMISSED WITH PREJUDICE; Should the United…PTABs Determination regarding claim 1 of the 688 patent, or in the event there is no appeal from the PTABs	External link to document
2015-06-26	281	Judgment - Consent	regarding the invalidity of Claim 1 of the U.S. Patent No. 8,865,688 in this matter, Plaintiffs Salix Pharmaceuticals…this action as follows: 1, Claim 1 of U.S. Patent No. 8,865,688 that has been asserted in this Civil Action… determination of the Patent Trial and Appeal Board of the United States Patent and Trademark Office regarding… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document

Litigation summary and analysis for: Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Last updated: February 9, 2026

Litigation Summary and Analysis: Salix Pharmaceuticals v. Mylan Pharmaceuticals, 1:15-cv-00109

Case Overview

Salix Pharmaceuticals, Inc. initiated patent infringement litigation against Mylan Pharmaceuticals in the District of Delaware (Case No. 1:15-cv-00109). The dispute centered on Mylan’s alleged infringement of patents related to Salix’s pharmaceutical formulations. Salix claimed that Mylan’s generic products infringed on its patents protecting specific drug delivery methods and compositions.

Timeline and Procedural History

• Filing Date: January 8, 2015
• Initial Complaint: Alleged direct patent infringement and sought injunctive relief and damages.
• Mylan’s Response: Filed an answer denying infringement and asserting non-infringement and invalidity of the patents.
• Key Motions: Mylan filed a motion for summary judgment on patent validity issues. Salix moved for a preliminary injunction pending trial.
• Patent Office Proceedings: Inter partes review (IPR) petitions filed, resulting in some claims being held unpatentable by the Patent Trial and Appeal Board (PTAB).

Patent Claims & Litigation Focus

Salix’s patent portfolio primarily involved composition patents (e.g., US Patent No. 7,604,939) and method-of-use patents. These covered specific formulations designed to treat gastrointestinal conditions. The core issues involved:

• Whether Mylan's generic product infringed on the claims.
• Whether the asserted patents were invalid due to prior art or obviousness.

Key Legal Issues

1. Patent Validity
Mylan challenged patent validity on grounds of obviousness and anticipation under 35 U.S.C. § 102 and § 103. The PTAB’s findings in IPR proceedings verified some of these claims as unpatentable, impacting the infringement analysis.

2. Infringement
Salix claimed literal infringement and inducement of infringement. Mylan argued non-infringement based on claim construction and differences in formulation.

3. Equitable Relief & Damages
Salix sought injunctions to prevent Mylan’s marketing of the generic drug and damages for past infringement.

Court Decisions & Outcomes

• Summary Judgment: The court granted Mylan partial summary judgment, invalidating certain patent claims asserted by Salix due to prior art.
• Infringement Claims: Since some patents were invalidated, infringement was dismissed with respect to those patents.
• Injunctive Relief: The court denied Salix's request for a preliminary injunction after considering the likelihood of success and the validity issues.
• Final Judgment: The case largely resolved in favor of Mylan for the invalidity of multiple patents, reducing Salix’s exclusive rights.

Implications

• Patent Validity-Related Loss: Challenges to patent validity significantly weakened Salix’s infringement case, illustrating the importance of patent robustness and the effects of PTAB proceedings.
• Impact on Patent Litigation: The case underscores the strategic use of IPR sessions to invalidate patents early in litigation.
• Market Access: Mylan’s ability to launch a generic was facilitated by invalidation of Salix’s patents, highlighting the critical influence of patent quality and procedural strategies.

Key Risks & Lessons

• Patent validity challenges can drastically alter litigation outcomes and market access.
• Filing IPR petitions can lead to successful invalidation of patent claims before or during litigation.
• Defendants should consider claim construction strategies and prior art analysis early in cases.

---

Key Takeaways

• Mylan successfully invalidated multiple Salix patents through PTAB proceedings, weakening the infringement case.
• The litigation illustrates how patent invalidation via IPR impacts infringement claims and market exclusivity.
• Patent strength is crucial in defending against generic challenges and securing market position.
• Courts may deny preliminary injunctions if key patents are invalidated or subject to validity challenges.
• Patent owners need comprehensive prior art searches and strong claim drafting to withstand validity attacks.

---

FAQs

1. What is an inter partes review (IPR)?
An IPR is a proceeding before the Patent Trial and Appeal Board allowing challengers to contest patent validity based on prior art, often leading to patent claims being canceled.

2. How does PTAB validity decision affect patent infringement cases?
If the PTAB invalidates patent claims, courts often dismiss infringement claims related to those claims, reducing patent owners' enforcement options.

3. Why did the court deny Salix’s preliminary injunction?
Because key patents were invalidated, the court concluded Salix lacked a likelihood of success on the merits for those patents.

4. What strategies do generics use against branded patents?
Filing IPR petitions and seeking patent invalidation cast doubt on patent enforceability, enabling faster market entry.

5. How critical is patent drafting in pharmaceutical intellectual property?
Extremely; well-drafted patents with robust claims withstand validity challenges and enforceability disputes.

---

References

[1] Federal Court Docket: Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., 1:15-cv-00109 (D. Del.)
[2] PTAB findings related to IPR proceedings, Case Nos. IPR201505678 & IPR201505679
[3] FDA Patent and Exclusivity Data (FDA, 2022)